The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Imidazoles as potential anticancer agents
Open accessAbstract
Cancer is a black spot on the face of humanity in this era of science and technology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Faulkner, D. J. (1990) · Natural Product Reports · doi:10.1039/np9900700269 · Cited by 4,866
Angiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60735-0 · Cited by 3,908
Angiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,482
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Rao, S. V., & Jollis, J. G. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.10.991 · Cited by 2,217
Targeting DNA topoisomerase II in cancer chemotherapy
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2607 · Cited by 1,791
The Role of Vascular Endothelial Growth Factor in Wound Healing
Bao, P., Kodra, A., Tomic-Canic, M., Golinko, M. S., Ehrlich, H. P., & Brem, H. (2009) · Journal of Surgical Research · doi:10.1016/j.jss.2008.04.023 · Cited by 1,211
McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., & Donehower, R. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-4-273 · Cited by 1,100
The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis
Falck, J., Mailand, N., Syljuåsen, R. G., Bartek, J., & Lukas, J. (2001) · Nature · doi:10.1038/35071124 · Cited by 1,085
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
Endothelial cells and VEGF in vascular development
Coultas, L., Chawengsaksophak, K., & Rossant, J. (2005) · Nature · doi:10.1038/nature04479 · Cited by 1,016
Etoposide: four decades of development of a topoisomerase II inhibitor
Hande, K. R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00228-7 · Cited by 949
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
Pommier, Y. (2009) · Chemical Reviews · doi:10.1021/cr900097c · Cited by 707
Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle
Jordan, A., Hadfield, J. A., Lawrence, N. J., & McGown, A. T. (1998) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199807)18:4<259::aid-med3>3.0.co;2-u · Cited by 673
Graves, P. R., Yu, L., Schwarz, J. K., Gales, J., Sausville, E. A., O'Connor, P. M., & Piwnica-Worms, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5600 · Cited by 544
Sher, T., Dy, G. K., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.3.355 · Cited by 498
Predicting the future burden of cancer
Bray, F., & Møller, B. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1781 · Cited by 486
Smith, M. A., Parkinson, D. R., Cheson, B. D., & Friedman, M. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.839 · Cited by 486
Targeting Microtubules for Cancer Chemotherapy
Zhou, J., & Giannakakou, P. (2005) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011053352569 · Cited by 468
Zhao, H., Watkins, J. L., & Piwnica-Worms, H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182557299 · Cited by 461
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., & O'Connor, P. M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.14.956 · Cited by 453
Camptothecin: current perspectives
Thomas, C. J., Rahier, N. J., & Hecht, S. M. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2003.11.036 · Cited by 451
Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription
Takai, H., Naka, K., Okada, Y., Watanabe, M., Harada, N., Saito, S., Anderson, C. W., Appella, E., Nakanishi, M., Suzuki, H., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf506 · Cited by 436
Carini, D. J., Duncia, J. V., Aldrich, P. E., Chiu, A. T., Johnson, A. L., Pierce, M. E., Price, W. A., Santella, J. B., & Wells, G. J. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00112a031 · Cited by 435
Efficient Synthesis of Imidazoles from Aldehydes and 1,2-Diketones Using Microwave Irradiation
Wolkenberg, S. E., Wisnoski, D. D., Leister, W. H., Wang, Y., Zhao, Z., & Lindsley, C. W. (2004) · Organic Letters · doi:10.1021/ol049682b · Cited by 432
Hirao, A., Cheung, A., Duncan, G., Girard, P.-M., Elia, A. J., Wakeham, A., Okada, H., Sarkissian, T., Wong, J. A., Sakai, T., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.18.6521-6532.2002 · Cited by 404
Faulkner, D. J. (2000) · Natural Product Reports · doi:10.1039/a809395d · Cited by 398
Retinoids regulate stem cell differentiation
Gudas, L. J., & Wagner, J. A. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22417 · Cited by 395
Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents
Xiao, Z., Chen, Z., Gunasekera, A. H., Sowin, T. J., Rosenberg, S. H., Fesik, S., & Zhang, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300229200 · Cited by 388
The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review
Wang, L. G., Liu, X. M., Kreis, W., & Budman, D. R. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050989 · Cited by 373
Gaba, M., & Mohan, C. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1495-5 · Cited by 366
Varia, M. A., Calkins-Adams, D. P., Rinker, L. H., Kennedy, A. S., Novotny, D. B., Fowler, W. C., & Raleigh, J. A. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1998.5163 · Cited by 342
Muscarine, imidazole, oxazole and thiazole alkaloids
Jin, Z. (2016) · Natural Product Reports · doi:10.1039/c6np00067c · Cited by 329
(2000) · PubMed · Cited by 314
Muscarine, imidazole, oxazole, and thiazole alkaloids
Jin, Z. (2011) · Natural Product Reports · doi:10.1039/c0np00074d · Cited by 311
Ueber die Einwirkung des Ammoniaks auf Glyoxal
Debus, H. (1858) · Justus Liebigs Annalen der Chemie · doi:10.1002/jlac.18581070209 · Cited by 308
Baviskar, A. T., Madaan, C., Preet, R., Mohapatra, P., Jain, V., Agarwal, A., Guchhait, S. K., Kundu, C. N., Banerjee, U. C., & Bharatam, P. V. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200235u · Cited by 294
Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
Sausville, E. A., Arbuck, S. G., Messmann, R., Headlee, D., Bauer, K. S., Lush, R. M., Murgo, A., Figg, W. D., Lahusen, T., Jaken, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2319 · Cited by 291
Synthesis and anticancer activity of some novel 2-substituted benzimidazole derivatives
Refaat, H. M. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.03.022 · Cited by 279
Stähelin, H., & von Wartburg, A. (1991) · PubMed · Cited by 278
DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors.
Chen, A. Y., Yu, C., Gatto, B., & Liu, L. F. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8131 · Cited by 268
Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Ali, I., Lone, M., Al-Othman, Z., Al-Warthan, A., & Sanagi, M. (2015) · Current Drug Targets · doi:10.2174/1389450116666150309115922 · Cited by 252
Self-citationA Submarine Journey: The Pyrrole-Imidazole Alkaloids
Forte, B., Malgesini, B., Piutti, C., Quartieri, F., Scolaro, A., & Papeo, G. (2009) · Marine Drugs · doi:10.3390/md7040705 · Cited by 229
(1996) · PubMed · Cited by 221
Structural Basis for Chk1 Inhibition by UCN-01
Zhao, B., Bower, M. J., McDevitt, P. J., Zhao, H., Davis, S. T., Johanson, K. O., Green, S. M., Concha, N. O., & Zhou, B.-B. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201233200 · Cited by 206
Kanthou, C., & Tozer, G. M. (2009) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2009.00651.x · Cited by 197
UCN-01, a selective inhibitor of protein kinase C from Streptomyces.
TAKAHASHI, I., KOBAYASHI, E., ASANO, K., YOSHIDA, M., & NAKANO, H. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.1782 · Cited by 186
Checkpoint Kinase Inhibitors: SAR and Radioprotective Properties of a Series of 2-Arylbenzimidazoles
Arienti, K. L., Brunmark, A., Axe, F. U., McClure, K., Lee, A., Blevitt, J., Neff, D. K., Huang, L., Crawford, S., Pandit, C. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0495935 · Cited by 175
Pyrazoline bearing benzimidazoles: Search for anticancer agent
Shaharyar, M., Abdullah, M. M., Bakht, M. A., & Majeed, J. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.09.032 · Cited by 170
Focal adhesion kinase and tumour angiogenesis
Lechertier, T., & Hodivala‐Dilke, K. (2012) · The Journal of Pathology · doi:10.1002/path.3018 · Cited by 169
(1990) · PubMed · Cited by 161
Newman, D. J., & Cragg, G. M. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043364982 · Cited by 161
Özkay, Y., Işıkdağ, İ., İncesu, Z., & Akalın, G. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.04.015 · Cited by 160
Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents
Wang, H., Morris-Natschke, S. L., & Lee, K. (1997) · Medicinal Research Reviews · Cited by 155
Hait, W. N. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3836 · Cited by 153
Chen, A. Y., Yu, C., Bodley, A. L., et al. (1993) · PubMed · Cited by 147
Lc, M., & Daly, A. K. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00356-7 · Cited by 143
Development trends for new cancer therapeutics and vaccines
Reichert, J. M., & Wenger, J. B. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.09.003 · Cited by 143
Saleem, K., Wani, W. A., Haque, A., et al. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.12.201 · Cited by 141
Novel benzimidazole–pyrimidine conjugates as potent antitumor agents
Abdel‐Mohsen, H. T., Ragab, F. A. F., Ramla, M. M., et al. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.02.011 · Cited by 138
Lu, X., Liu, X., Wan, B., Franzblau, S. G., Chen, L., Zhou, C., & You, Q. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.01.007 · Cited by 130
Synthesis and antitumor activity of 1-substituted-2-methyl-5-nitrobenzimidazoles
Ramla, M. M., Omar, M. A., El-Khamry, A.-M. M., et al. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.06.033 · Cited by 125
Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest.
Kamath, K., & Jordan, M. A. (2003) · PubMed · Cited by 120
Hranjec, M., Pavlović, G., Marjanović, M., Kralj, M., & Karminski-Zamola, G. M. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.02.022 · Cited by 119
Demirayak, Ş., Kayağil, İ., & Yurttaş, L. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.11.007 · Cited by 119
Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia
Kath, R., Blumenstengel, K., Fricke, H.-J., & Höffken, K. (2001) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320000180 · Cited by 117
New tubulin targeting agents currently in clinical development
Carlson, R. O. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.5.707 · Cited by 113
R115866 Inhibits All-trans-Retinoic Acid Metabolism and Exerts Retinoidal Effects in Rodents
Stoppie, P., Borgers, M. J., Borghgraef, P., Dillen, L., Goossens, J., Sanz, G., Szel, H., Hove, C. V., Nyen, G. V., Nobels, G., et al. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39233-x · Cited by 112
Novel Combretastatin Analogues Endowed with Antitumor Activity
Simoni, D., Romagnoli, R., Baruchello, R., Rondanin, R., Rizzi, M., Pavani, M. G., Alloatti, D., Giannini, G., Marcellini, M., Riccioni, T., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0510732 · Cited by 109
Zoledronic acid: A new parenteral bisphosphonate
Li, E. C., & Davis, L. E. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80327-2 · Cited by 107
Ramla, M. M., Omar, M. A., Tokuda, H., et al. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.04.010 · Cited by 105
The role of FAK in tumor metabolism and therapy
Zhang, J., & Hochwald, S. N. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.003 · Cited by 104
Hawwa, A. F., Millership, J. S., Collier, P. S., et al. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03248.x · Cited by 103
Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist
Hancock, A. A., Bennani, Y. L., Bush, E. N., Esbenshade, T. A., Faghih, R., Fox, G. B., Jacobson, P. B., Knourek-Segel, V. E., Krueger, K. M., Nuss, M. E., et al. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.01.015 · Cited by 102
Disrupting the Scaffold to Improve Focal Adhesion Kinase–Targeted Cancer Therapeutics
Cance, W. G., Kurenova, E., Marlowe, T. A., & Golubovskaya, V. (2013) · Science Signaling · doi:10.1126/scisignal.2004021 · Cited by 98
Neochoritis, C. G., Zarganes‐Tzitzikas, T., Tsoleridis, C. A., et al. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.11.018 · Cited by 98
Zhan, P., Liu, X., Zhu, J., Fang, Z., Li, Z., Pannecouque, C. C., & Clercq, E. D. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.07.028 · Cited by 87
Beerman, T. A., McHugh, M. M., Sigmund, R. D., Lown, J. W., Rao, K. E., & Bathini, Y. (1992) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(92)90098-k · Cited by 87
Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity
heusden, J. V., Ginckel, R. V., Bruwiere, H., Moelans, P., Janssen, B., Floren, W., van der Leede, B. J., Dun, J. V., Sanz, G., Venet, M., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600056 · Cited by 86
Phase I evaluation of all-trans-retinoic acid in adults with solid tumors.
Lee, J. S., Newman, R. A., Lippman, S. M., et al. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.5.959 · Cited by 85
Copp, B. R., Fairchild, C. R., Cornell, L., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980294n · Cited by 85
Kiselyov, A. S., Semenova, M. N., Chernyshova, N. B., Leitão, A., Samet, A. V., Kislyi, K. A., Raihstat, M. M., Oprea, T. I., Lemcke, H., Lantow, M., et al. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.12.072 · Cited by 83
Balderas-Renterı́a, I., González-Barranco, P., García, A., Banik, B. K., & Rivera, G. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803251593 · Cited by 83
Sartorelli, A. C., & Creasey, W. A. (1969) · Annual Review of Pharmacology · doi:10.1146/annurev.pa.09.040169.000411 · Cited by 80
Gowda, N. R. T., KAVITHA, C. V., CHIRUVELLA, K. K., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.06.103 · Cited by 74
Beck, D. E., Agama, K., Marchand, C., Chergui, A., Pommier, Y. G., & Cushman, M. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401814y · Cited by 74
Bendamustine: something old, something new
Tageja, N., & Nagi, J. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1317-x · Cited by 73
Skibo, E. B., Islam, I., Heileman, M. J., et al. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00027a010 · Cited by 70
4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK-1 inhibitors
Ni, Z., Barsanti, P. A., Brammeier, N., Diebes, A., Poon, D. J., Ng, S. S. M., Pecchi, S., Pfister, K. B., Renhowe, P. A., Ramurthy, S., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.03.059 · Cited by 70
Raats, J., Falkson, G., & Hc, F. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.111 · Cited by 67
Dao, P., Smith, N., Tomkiewicz, C., Yen‐Pon, E., Camacho‐Artacho, M., Lietha, D., Herbeuval, J.-P., Coumoul, X., Garbay, C., & Chen, H. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500784e · Cited by 62
Optimisation of imidazole compounds as selective TAAR1 agonists: Discovery of RO5073012
Galley, G., Stalder, H., Goergler, A., Hoener, M. C., & Norcross, R. D. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.06.060 · Cited by 62
A review on pharmacophoric designs of antiproliferative agents
Rana, A., Alex, J. M., Chauhan, M., Joshi, G., & Kumar, R. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1196-5 · Cited by 58
Skibo, E. B., & SCHULZ, W. G. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00073a002 · Cited by 58
Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma
Chen, J., Wang, Z., Lü, Y., Dalton, J. T., Miller, D. D., & Li, W. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.073 · Cited by 55
Investigation of cross-link formation in DNA by the alkylating cytostatica IMET 3106, 3393 and 3943
Hartmann, M., & Zimmer, C. (1972) · Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis · doi:10.1016/0005-2787(72)90282-1 · Cited by 52
Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells
Armstrong, J. L., Ruiz, M. T., Boddy, A. V., Redfern, C. P. F., Pearson, A. D. J., & Veal, G. J. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602398 · Cited by 50
Tolner, B., Hartley, J. A., & Hochhauser, D. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.4.699 · Cited by 49
Nanotech Revolution for the Anti-Cancer Drug Delivery through Blood- Brain-Barrier
Caraglia, M., Rosa, G. D., Salzano, G., Santini, D., Lamberti, M., Sperlongano, P., Lombardi, A., Abbruzzese, A., & Addeo, R. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912799277421 · Cited by 48
Boruah, R. C., & Skibo, E. B. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00037a013 · Cited by 44
Özpolat, B., Mehta, K., & Lopez‐Berestein, G. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500174737 · Cited by 41
New Dermatological Agents for the Treatment of Psoriasis
Thacher, S. M., Vasudevan, J., Tsang, K.-Y., Nagpal, S., & Chandraratna, R. A. S. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0000214 · Cited by 41
Phase II study of pibenzimol in pancreatic cancer
Kraut, E. H., Fleming, T., Segal, M., et al. (1991) · Investigational New Drugs · doi:10.1007/bf00194556 · Cited by 39
Synthesis and in vitro cytotoxic evaluation of some thiazolylbenzimidazole derivatives
Luo, Y., Xiao, F., Qian, S., Lu, W. P., & Yang, B. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.11.014 · Cited by 34
Singh, K., Verma, V., Yadav, K., Sreekanth, V., Kumar, D., Bajaj, A., & Kumar, V. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.055 · Cited by 34
Sun, B., Liu, K., Han, J., Zhao, L., Su, X. Y., Lin, B., Zhao, D., & Cheng, M. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.08.019 · Cited by 33
Neff, D. K., Lee-Dutra, A., Blevitt, J. M., Axe, F. U., Hack, M. D., Buma, J., Rynberg, R., Brunmark, A. B., Karlsson, L., & Breitenbucher, J. G. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.09.098 · Cited by 33
Gopinath, G., Sagurthi, S. R., Shyam, P., Achaiah, G., & Krupadanam, G. L. D. (2014) · RSC Advances · doi:10.1039/c4ra09945a · Cited by 31
Gomaa, M. S., Bridgens, C. E., Aboraia, A. S., Veal, G. J., Redfern, C. P. F., Brancale, A., Armstrong, J. L., & Simons, C. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101583w · Cited by 30
Activity of the Triazole Antifungal R126638 as Assessed by Corneofungimetry
Piérard-Franchimont, C., Ausma, J., Wouters, L., Vroome, V., Vandeplassche, L. M., Borgers, M. J., Cauwenbergh, G. F. M. J., & Pierard, G. (2005) · Skin Pharmacology and Physiology · doi:10.1159/000089143 · Cited by 29
Iradyan, M. A., Iradyan, N. S., Stepanyan, G. M., Arsenyan, F. G., & Garibdzhanyan, B. T. (2010) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-010-0425-6 · Cited by 28
New Therapeutic Strategies for Cancer and Neurodegeneration Emerging from Yeast Cell-based Systems
Pereira, C., Leao, M., Soares, J., Bessa, C., & Saraiva, L. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802430422 · Cited by 28
Ng, R. A., Guan, J., Alford, V. C., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.11.047 · Cited by 27
Gomaa, M. S., Bridgens, C. E., Veal, G. J., Redfern, C. P. F., Brancale, A., Armstrong, J. L., & Simons, C. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200695m · Cited by 23
Synthesis of 5‐Substituted 2‐Methylbenzimidazoles with Anticancer Activity
El‐Naem, S. I., El‐Nzhawy, A. O., Diwani, H. I. E., & Hamid, A. O. A. (2003) · Archiv der Pharmazie · doi:10.1002/ardp.200390005 · Cited by 21
Recent developments in the clinical activity of topoisomerase-1 inhibitors
Haglof, K. J., Popa, E., & Höchster, H. S. (2006) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2006.05.010 · Cited by 16
A High‐Content, Cell‐Based Screen Identifies Micropolyin, A New Inhibitor of Microtubule Dynamics
Rycker, M. D., Rigoreau, L. J. M., Dowding, S. N., & Parker, P. J. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00817.x · Cited by 16
Mulvihill, M. J., Kan, J. L. C., Beck, P., Bittner, M., Cesario, C., Cooke, A. R., Keane, D. M., Nigro, A., Nillson, C., Smith, V., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.01.044 · Cited by 16
Nørregaard, A., Jensen, S. S., Kolenda, J., Aaberg-Jessen, C., Christensen, K. G., Jensen, P. H., Schrøder, H. D., & Kristensen, B. W. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9300-9 · Cited by 14
Ahmad, M. (2011) · Scientia Pharmaceutica · doi:10.3797/scipharm.1106-18 · Cited by 13
Yang, Y., Jin, C. S., Li, H., He, Y., LIU, Z., Bai, L., & DOU, K. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.389 · Cited by 12
Synthesis and Antiangiogenic Activity of N-Alkylated Levamisole Derivatives
Hansen, A. N., BENDIKSEN, C. D., Sylvest, L., Friis, T., Stærk, D., Jørgensen, F. S., Olsen, C. A., & Houen, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045405 · Cited by 10
DNA Topoisomerases in Cancer Therapy
(2003) · Springer eBooks · doi:10.1007/978-1-4615-0141-1 · Cited by 7
Chapter 12. Intracellular signaling targets for cancer chemosensitization
Gesner, T. G., & Harrison, S. D. (2002) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(02)37013-1 · Cited by 4
Metadata
- Authors
- Ali, I., Lone, M. N., & Aboul-Enein, H. Y.
- Venue
- Med. Chem. Commun.
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2017
- Volume
- 8
- Issue
- 9
- Pages
- 1742-1773
- ISSN
- 2040-2503 (ISSN-L)
- 2040-2511
- OpenAlex
- W2605474943
- Cited by
- 409
- References
- 127
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.